Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.52 EUR | -1.31% | -2.28% | -5.56% |
Apr. 17 | K+S : JP Morgan reiterates its Buy rating | ZD |
Apr. 11 | K+S : Deutsche Bank gives a Neutral rating | ZD |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.67 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company does not generate enough profits, which is an alarming weak point.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.34 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Agricultural Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.56% | 2.63B | B | ||
-.--% | 11.13B | - | B+ | |
-7.28% | 7.21B | A | ||
+7.47% | 6.84B | B- | ||
-3.91% | 5.92B | B+ | ||
-6.14% | 5.6B | B | ||
-10.44% | 5.57B | - | C- | |
+31.35% | 5.14B | B- | ||
-13.45% | 4.56B | C+ | ||
+17.77% | 4.4B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SDF Stock
- Ratings K+S AG